Radiological Presentation of a Patient With Multiple Sclerosis and Hepatic Disorder
Abstract
In this case study, we presented the radiological characteristics of a 43-year-old female patient diagnosed with Multiple Sclerosis (MS). Following mitoxantrone administration, she developed liver failure. Magnetic Resonance Imaging (MRI) revealed multiple periventricular lesions in T2 and bilateral involvement of putamen and Globus Pallidus (GP) areas in T1 sequences.
[1] Hegde AN, Mohan S, Lath N, Tchoyoson Lim CC. Differential diagnosis for bilateral abnormalities of the basal ganglia and thalamus. RadioGraphics. 2011; 31(1):5-30. [DOI:10.1148/rg.311105041] [PMID]
[2] Antonazzo IC, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E, et al. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA adverse event reporting system. Multiple Sclerosis Journal. 2019; 25(12):1633-40. [DOI:10.1177/1352458518799598] [PMID]
[3] Doosti R, Togha M, Moghadasi AN, Aghsaie A, Azimi AM, Khorramnia S, et al. Evaluation of the risk of cervical cancer in patients with Multiple Sclerosis treated with cytotoxic agents: A cohort study. Iranian Journal of Neurology. 2018; 17(2):64-70. [PMID] [PMCID]
[4] Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology. 2010; 74(22):1822-6. [DOI:10.1212/WNL.0b013e3181e0f7e6] [PMID] [PMCID]
[5] Llesuy SF, Arnaiz SL. Hepatotoxicity of mitoxantrone and doxorubicin. Toxicology. 1990; 63(2):187-98. [DOI:10.1016/0300- 483X(90)90042-F] Salehizadeh
[2] Antonazzo IC, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E, et al. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA adverse event reporting system. Multiple Sclerosis Journal. 2019; 25(12):1633-40. [DOI:10.1177/1352458518799598] [PMID]
[3] Doosti R, Togha M, Moghadasi AN, Aghsaie A, Azimi AM, Khorramnia S, et al. Evaluation of the risk of cervical cancer in patients with Multiple Sclerosis treated with cytotoxic agents: A cohort study. Iranian Journal of Neurology. 2018; 17(2):64-70. [PMID] [PMCID]
[4] Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology. 2010; 74(22):1822-6. [DOI:10.1212/WNL.0b013e3181e0f7e6] [PMID] [PMCID]
[5] Llesuy SF, Arnaiz SL. Hepatotoxicity of mitoxantrone and doxorubicin. Toxicology. 1990; 63(2):187-98. [DOI:10.1016/0300- 483X(90)90042-F] Salehizadeh
| Files | ||
| Issue | Vol 4 No 4 (2019): Autumn | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/crcp.v4i4.2385 | |
| Keywords | ||
| Multiple sclerosis Liver dysfunction Brain Magnetic Resonance Imaging | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Salehizadeh S, Naser Moghadasi A. Radiological Presentation of a Patient With Multiple Sclerosis and Hepatic Disorder. CRCP. 2020;4(4):102-104.
